Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.
Shikha Baghel Chauhan, Naziya Akhtar, Chirag Jain, Indu Singh
CNS Neurol Disord Drug Targets March 11, 2026 DOI: 10.2174/0118715273434237251212095005 (opens in new tab) via PubMed
Summary
AI-generated from the abstractThis work explores how psychedelic compounds can be delivered to the brain more effectively to treat central nervous system disorders. It bridges molecular pharmacology with therapeutic innovation by discussing strategies for targeted neurodelivery, aiming to enhance efficacy and reduce side effects. The paper reviews current understanding of how psychedelics interact with neural targets and proposes methods to optimize their transport across the blood-brain barrier. The goal is to improve clinical outcomes for conditions such as depression, anxiety, and addiction by ensuring that these compounds reach the right brain regions in the right amounts.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Key finding | Strategic neurodelivery of psychedelic compounds could improve therapeutic outcomes for CNS disorders by enhancing targeted brain delivery and reducing side effects. |
Abstract
Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.